Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Aplidin study in previously treated advanced or metastatic urothelial transitional cell carcinoma
2004-001118-15Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Mar 2005
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plitidepsin in transitional cell carcinoma (TCC), sponsored by PharmaMar. Primary endpoint: Objective tumor response. Started Mar 2005; status: completed.
02
Drugs
plitidepsin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2004-001118-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001118-15.